CL2019002174A1 - Composición que comprende capecitabina de liberación inmediata y liberación prolongada. - Google Patents

Composición que comprende capecitabina de liberación inmediata y liberación prolongada.

Info

Publication number
CL2019002174A1
CL2019002174A1 CL2019002174A CL2019002174A CL2019002174A1 CL 2019002174 A1 CL2019002174 A1 CL 2019002174A1 CL 2019002174 A CL2019002174 A CL 2019002174A CL 2019002174 A CL2019002174 A CL 2019002174A CL 2019002174 A1 CL2019002174 A1 CL 2019002174A1
Authority
CL
Chile
Prior art keywords
release
composition
capecitabine
prolonged
immediate release
Prior art date
Application number
CL2019002174A
Other languages
English (en)
Inventor
Kashyap Gandhi
Piyush Patel
Manish Patel
Manish Chauhan
Ashish Sehgal
Original Assignee
Intas Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intas Pharmaceuticals Ltd filed Critical Intas Pharmaceuticals Ltd
Publication of CL2019002174A1 publication Critical patent/CL2019002174A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A UNA COMPOSICIÓN FARMACÉUTICA DE CAPECITABINA, EN DONDE DICHA COMPOSICIÓN COMPRENDE CAPECITABINA DE LIBERACIÓN INMEDIATA Y CAPECITABINA DE LIBERACIÓN PROLONGADA. ADEMÁS, LA PRESENTE INVENCIÓN DESCRIBE UN PROCEDIMIENTO PARA LA PREPARACIÓN DE DICHA COMPOSICIÓN.
CL2019002174A 2017-02-06 2019-08-02 Composición que comprende capecitabina de liberación inmediata y liberación prolongada. CL2019002174A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN201721004194 2017-02-06

Publications (1)

Publication Number Publication Date
CL2019002174A1 true CL2019002174A1 (es) 2019-11-29

Family

ID=63040300

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019002174A CL2019002174A1 (es) 2017-02-06 2019-08-02 Composición que comprende capecitabina de liberación inmediata y liberación prolongada.

Country Status (13)

Country Link
US (1) US20190358253A1 (es)
EP (1) EP3576721A4 (es)
JP (1) JP2020514314A (es)
CN (1) CN110290779A (es)
AU (1) AU2018214291A1 (es)
BR (1) BR112019016028A2 (es)
CA (1) CA3051040A1 (es)
CL (1) CL2019002174A1 (es)
IL (1) IL268137A (es)
MX (1) MX2019009230A (es)
PH (1) PH12019501689A1 (es)
RU (1) RU2019126572A (es)
WO (1) WO2018142359A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070122481A1 (en) * 1998-11-02 2007-05-31 Elan Corporation Plc Modified Release Compositions Comprising a Fluorocytidine Derivative for the Treatment of Cancer
JP2008535920A (ja) * 2005-04-12 2008-09-04 エラン・ファルマ・インターナショナル・リミテッド 癌の治療のための、フルオロシチジン誘導体を含む改変放出組成物
MX2011011596A (es) * 2010-03-31 2012-02-01 Keryx Biopharmaceuticals Inc Perifosina y capecitabina como un tratamiento combinado para cancer.
US20200054659A1 (en) * 2015-06-13 2020-02-20 Intas Pharmaceuticals Ltd. Extended release capecitabine capsules
CN104997744B (zh) * 2015-08-04 2018-01-23 青岛市中心医院 一种高稳定性卡培他滨片剂及其制备方法

Also Published As

Publication number Publication date
JP2020514314A (ja) 2020-05-21
EP3576721A1 (en) 2019-12-11
US20190358253A1 (en) 2019-11-28
EP3576721A4 (en) 2020-07-22
MX2019009230A (es) 2019-09-10
CN110290779A (zh) 2019-09-27
BR112019016028A2 (pt) 2020-03-31
RU2019126572A (ru) 2021-03-09
AU2018214291A1 (en) 2019-08-01
IL268137A (en) 2019-09-26
PH12019501689A1 (en) 2020-03-09
CA3051040A1 (en) 2018-08-09
WO2018142359A1 (en) 2018-08-09

Similar Documents

Publication Publication Date Title
CL2023001910A1 (es) Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo
CL2020001048A1 (es) Anticuerpos monoclonales contra bcma. (divisional solicitud 201800281)
ECSP21072161A (es) Composiciones de liberación retardada de linaclotida
SV2018005709A (es) 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa
MX2018014154A (es) Polinucleotidos moduladores.
CL2016002772A1 (es) Composiciones de insulina de rápida acción
MX2016014247A (es) Conjugados de anticuerpo-farmaco anti-proteina tirosina quinasa 7 (anti-ptk7).
MX2020011104A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
MX374012B (es) Formas solidas cristialinas de 6-carboxi-2-(3,5-diclorofenil)-benzoxazol.
MX2017005236A (es) Profarmacos de carbidopa y l-dopa y metodos de uso.
SV2018005643A (es) Composiciones de insulina de rapida accion
CO2019008103A2 (es) Composiciones farmacéuticas para terapia de combinación
MX2018002416A (es) Derivados de 1,7-diaril-1,6-heptadien-3,5-diona, procedimiento para la preparación y uso de los mismos.
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
BR112018003178A2 (pt) absorvente feminino com braçadeiras de barreira
CL2020001264A1 (es) Compuestos y métodos sintéticos para la preparación de retinodes específicos del receptor x retinoide.
MX2015012833A (es) Composiciones antibioticas de ceftolozano.
MX2018007084A (es) Inhibidores de la tirosina quinasa de bruton y metodos de su uso.
MX386055B (es) Uso de medicamentos para disminuir la evolución de la enfermedad de parkinson.
BR112017015159A2 (pt) preparação e uso de produtos plaquetários
SV2017005412A (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
CL2019001053A1 (es) Formulaciones farmacéuticas y métodos para prepararlas.
AR104591A1 (es) Piroglutamato de vortioxetina
AR108616A1 (es) Formulación combinada de tres compuestos antivirales
MX2017013879A (es) Composiciones que comprenden anakinra.